Increased Mortality in Kidney Transplant Recipients During the Delta/Omicron Era of the COVID‐19 Pandemic Despite Widespread Vaccination

Clinical Transplantation, Год журнала: 2025, Номер 39(1)

Опубликована: Янв. 1, 2025

ABSTRACT Introduction The incidence of mortality late in the pandemic, particularly after widespread vaccine availability, is not well understood. Herein, we elucidate effect this impact COVID pandemic as risk factors for during it. Methods primary end point was death with a functioning graft secondary endpoints rates subgroups and at different time intervals pandemic. Results Despite vaccination, kidney transplant (KTx) recipients almost doubled COVID‐19 era (6.40 deaths per 100 person years vs. 3.54 pre‐COVID). Mortality increased all racial/ethnic groups but more Native Americans, Hispanics, African Americans compared to non‐Hispanic Caucasians. highest rate occurred Delta Omicron frames. In contrast general population, evenly spread across age KTx recipients. Conclusions were extremely high, than doubling some groups. We conclude that population vulnerable group suggests need further research into management variants future.

Язык: Английский

---

Leukocyte Count in Solid Organ Transplant Recipients After SARS-CoV-2 mRNA Vaccination and Infection

Vaccines, Год журнала: 2025, Номер 13(2), С. 103 - 103

Опубликована: Янв. 22, 2025

Background: Solid organ transplant (SOT) recipients are at risk of severe COVID-19. Vaccination is an important preventive measure but may have side effects, including decreased leukocyte counts. We aimed to describe the prevalence and relative incidence counts changes in before after SARS-CoV-2 mRNA vaccination infection SOT recipients. Methods: Changes from each vaccine dose were investigated using linear mixed models. determined infection. Self-controlled case series analysis was used investigate whether period either or associated with count. Results: included 228 adult kidney, lung, liver Prior first dose, mean count 7.3 × 109 cells/L (95% CI 6.9–7.6). Both counts, remained unchanged regardless number doses provided. There no association between (incidence rate ratio (IRR): 0.6; 95% CI: 0.2–2.1; p = 0.461). In contrast, increased a (IRR: 7.1; 2.8–18.1; < 0.001). Conclusions: not did affect higher

Язык: Английский

---

Respiratory infections in lung transplant recipients

Current Opinion in Infectious Diseases, Год журнала: 2025, Номер unknown

Опубликована: Фев. 10, 2025

Morbidity and mortality rates after lung transplantation still remain higher than other forms of solid organ transplantation, primarily due to a risk infections the development chronic allograft dysfunction. Thus, tiered approach highlighting most significant respiratory pathogens including common opportunistic along with diagnostic, treatment prevention strategies, vaccination prophylaxis is needed. The need for intense immunosuppressive therapy prevent rejection, coupled transplanted lung's constant exposure environment impaired local defence mechanisms leads frequent infections. Viral bacterial are while fungal mainly involve tracheobronchial tract but may be fatal in case disseminated disease. Some infectious agents known trigger acute rejection or contribute Invasive testing form bronchoscopy bronchoalveolar lavage standard increasing experience point care gained allow early preemptive therapy. Timely diagnosis, treatment, ongoing monitoring essential, this can difficult wide variety potential pathogens.

Язык: Английский

---

Editorial for the Special Issue “Infectious and Tropical Diseases: Symptoms, Diagnosis and Treatment”

Medicina, Год журнала: 2025, Номер 61(3), С. 377 - 377

Опубликована: Фев. 22, 2025

For centuries, humans have faced the devastating wrath of outbreaks, epidemics and pandemics caused by infectious diseases [...]

Язык: Английский

---

Navigating Coronavirus Disease 2019 in Immunocompromised Populations

Infectious Disease Clinics of North America, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective

Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Март 18, 2025

Immunocompromised patients are disproportionately impacted by severe disease, hospitalization, and mortality associated with coronavirus disease 2019 (COVID-19). To optimize the management of these in clinical practice, we convened an expert panel to review current evidence on acute respiratory syndrome 2 (SARS-CoV-2) vaccine responses COVID-19 immunocompromised populations. We identified four main groups—solid organ transplant recipients, receiving allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T therapy, treated for hematologic malignancies, inflammatory diseases—who mount suboptimal humoral SARS-CoV-2 vaccination at increased risk COVID-19-related outcomes. A wide range factors were reduced and/or poor outcomes, most commonly older age, comorbidities, type number immunosuppressive therapies. believe that early identification close monitoring at-risk patients, plus regular booster vaccinations, prophylactic monoclonal antibody non-pharmacologic prevention measures, prompt antiviral treatment, other mitigation strategies, critical protect against infection COVID-19. Although people will fully recover from COVID-19, who less able fight more likely be hospitalized die improve treatment people, 10 experts France met discuss latest medical research this area. The focused groups people: (1) transplants; (2) transplants therapy; (3) being blood cancers; (4) diseases (such as rheumatoid arthritis). These protected after develop forms pre-existing conditions diabetes, obesity, heart, lung, kidney disease), immunosuppressants. agreed it is important quickly identify clinic, so they can receive vaccines every 6 months. For unable build up their immunity vaccination, treatments also used prevent infection. In recommend using therapies nirmatrelvir/ritonavir remdesivir) becoming severe. addition measures mask wearing social distancing), strategies help

Язык: Английский

---

Unlocking the potential of remdesivir: innovative approaches to drug delivery

Drug Delivery and Translational Research, Год журнала: 2025, Номер unknown

Опубликована: Апрель 17, 2025

Abstract Given the recurrent waves of COVID-19 and emergence new viral infections, optimizing potential remdesivir as an antiviral agent is critical. While several reviews have explored efficacy remdesivir, few comprehensively addressed its challenges, such necessity for intravenous infusion, suboptimal lung accumulation, safety concerns related to formulation. This review critically examines these challenges while proposing innovative solutions effective combinations with other agents repurposed drugs. By highlighting role complex generics, we aim enhance therapeutic in ways not previously discussed existing literature. Furthermore, address development novel drug delivery systems which specifically improve remdesivir's pharmacological profile. analyzing recent findings, assess both successes limitations current approaches, providing insights into ongoing strategies further optimization. uniquely focuses on targeted formulations, thereby maximizing benefits broadening application combating emerging threats. In doing so, fill a critical gap literature, offering comprehensive overview that informs future research clinical strategies. Graphical

Язык: Английский

---

Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center

Annals of Medicine, Год журнала: 2024, Номер 56(1)

Опубликована: Июнь 3, 2024

Background Literature on the safety of remdesivir in hospitalized COVID-19 patients with severe renal impairment is limited. We aimed to investigate and effectiveness this population.

Язык: Английский

---

The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines

Viruses, Год журнала: 2024, Номер 16(6), С. 860 - 860

Опубликована: Май 28, 2024

As solid organ transplant (SOT) recipients remain at risk of severe outcomes after SARS-CoV-2 infections, vaccination continues to be an important preventive measure. In SOT previously vaccinated with least three doses BNT162b2, we investigated humoral responses BNT162b2 booster doses. Anti-SARS-CoV-2 receptor binding domain (RBD) immunoglobulin G (IgG) was measured using in-house ELISA. Linear mixed models were fitted investigate the change in geometric mean concentration (GMC) anti-SARS-CoV-2 RBD IgG participants intervals more or less than six months between last two vaccine. We included 107 a interval vaccine doses, found 1.34-fold GMC per month (95% CI 1.25–1.44), while 1.09-fold 0.89–1.34) resulting rate ratio 0.82 0.66 1.01, p = 0.063). conclusion, administration identical COVID-19 mRNA boosters within may result limited immunogenicity dose.

Язык: Английский

---

Risk factors for severe outcomes of coronavirus disease 2019 through the waves of the pandemic: Comparing patients with and without solid organ transplantation

Transplant Infectious Disease, Год журнала: 2024, Номер 26(5)

Опубликована: Июль 9, 2024

While coronavirus disease 2019 (COVID-19) is no longer a public health emergency, certain patients remain at risk of severe outcomes. To better understand changing profiles, we studied the factors for with and without solid organ transplantation (SOT) through various waves pandemic.

Язык: Английский

---